Objective: To study the predictive power of serum selenium with regard to cancer mortality in a large sample of the Belgian population given the lack of coherence in the results of observational epidemiological studies in this domain. Design: A prospective case-control study within a stratified sample of the Belgian male and female population. Subjects: A total of 201 cases randomly selected from all cancer deaths (N ¼ 343) during a 10-y mortality follow-up of a large age-and sex-stratified sample of the total Belgian population aged 25-74 y were matched for age and gender with 603 controls. Statistics: Conditional logistic regression for both univariate and multivariate analyses using tertile distribution of serum selenium in controls. Odds ratios (ORs) are adjusted for 10 baseline characteristics. Results: Unadjusted ORs of cancer deaths taking the highest tertile of serum selenium as a reference: in male subjects T1/T3 is 2.2 (CI 1.3-3.7) (P for trend 0.011), whereas in female subjects a nonsignificant OR of 0.8 is observed. In multivariate analyses, no significant modifications of the ORs are observed for the predictive relation of serum selenium with cancer mortality. Besides serum selenium, beta-carotene intake and smoking are independent predictors in male subjects. Conclusions: In this nested case-control study of a stratified sample from the Belgian population, serum selenium is an independent predictor of cancer mortality in male subjects only, in a country with rather high serum selenium levels with respect to most other European countries.
Introduction
Selenium has been suggested to be anticarcinogenic and plays an important role in cellular defence against oxidative stress through different pathogenetic pathways involving both increased immune response and its ability to produce antitumorigenic metabolites (Rayman, 2000) . Whereas the biological plausibility as a criterion of causal relation is firm, the epidemiological evidence collected during the past 20 y lacks coherence. Most of the studies are nested case-control within a prospective study. Selenium status was measured by its serum level or toenail content. These studies originated from a few countries: US, Finland, Sweden, Norway and the Netherlands.
Several studies observed an inverse relation of serum selenium with cancer in general (Salonen et al, 1984 (Salonen et al, , 1985 Fex et al, 1987; Knekt et al, 1990) only in male subjects (Willett et al, 1983; Kok et al, 1987) or cancer at specific sites: lung cancer ( Van den Brandt et al, 1993a; Knekt et al, 1998) , advanced prostate cancer (Yoshizawa et al, 1998) , bladder cancer (Helzlsouer et al, 1989) , ovarian cancer (Helzlsouer et al, 1996) , thyroid cancer (Glattre et al, 1989) , stomach cancer ( Van den Brandt et al, 1993b) or upper gastrointestinal tract (Knekt et al, 1988) . Whereas others did not observe an inverse association with cancer in general neither in men (Virtamo et al, 1987; Coates et al, 1988) nor in women (Garland et al, 1995) or cancer at specific sites: lung cancer (Menkes et al, 1986; Nomura et al, 1987) , colon cancer (Schrober et al, 1987) , colorectal cancer (Knekt et al, 1988 ; Van den Brandt et al, 1993b) , breast cancer (Van Noord et al, 1987; Hunter et al, 1990) or prostate cancer (Hartman et al, 1998) . Comstock et al (1992) reviewing 10 studies looking at different cancer sites observed that 'the majority of the studies reported lower serum levels among cases than among controls'. Thus, the evidence from observational epidemiology both in terms of strength of association, gradation and coherence between studies is still weak. Randomised controlled trials, a higher level of evidence-based medicine, originated in China, a country known for selenium deficiency (Blot et al, 1993) and in the US (Clark et al, 1996) . The former showed that a preparation of Vitamin E, betacarotene and selenium significantly reduced total cancer mortality by 13% and stomach mortality by 21%, whereas the latter showed in subjects with nonmelanoma skin cancer supplemented with selenium a significant reduction of prostate, lung and colorectal cancer.
The present investigation is a case-control study nested within a prospective study of a stratified national sample of the Belgian population. Up to now, it is the only study on the predictive power of serum selenium on cancer in that country and taking into account several other nutrients.
Material and methods
The design of the Belgian Interuniversity Study on Nutrition and Health (BIRNH) has been published in length (Nutrition and Health: an interuniversity study, 1984). Therefore, the principal features concerning this population-based stratified sample aged 25-74 y will only be summarised. From each of the 43 districts of Belgium, 3-5 municipalities were selected meaning a total of 170 municipalities. The municipality with the highest population density was chosen ex officio, while two to four other municipalities were selected at random. The National Register or local voting lists were used for the selection of the study sample. The sample was drawn and the survey took place between 1980 and 1984. The screening included 5549 male and 5353 female subjects representing 38% of the randomly selected stratified sample; 10% of the nonresponders were contacted and 65% of them accepted a dietary survey. No statistical differences were found between this sample and the participants in terms of macro-and micronutrients intake.
The technique of the 24 h food record was used for dietary survey. A preprinted questionnaire was sent to the subjects a few days before the visit indicating the day during which a recording of the entire food consumption was requested. This form was fully reviewed by a trained dietitian and the information translated into quantities for 156 food items. The translation from food items to nutrients was made by a computer. The program was developed based on the Dutch food composition tables, on the tables from Paul and Southgate (1980) for fibre and on food composition data available in Belgium for local food items like certain margarines. Fat and alcohol intakes, initially expressed in grams per day, were converted into percentages of total calories intake.
Height and weight were measured on a scale type Seca 710 with the subjects undressed to the waist and shoes off.
Smoking behaviour was obtained by a self-administered questionnaire.
A nonfasting blood sample was taken from an antecubital vein in supine position during the baseline examination. A few hours later, serum was separated and kept in a deepfreezer at À201C. Serum selenium was determined by graphite furnace atomic absorption spectroscopy with Zeeman background correction and each sample was measured in triplicate (Nève et al, 1987) . Quality control was ensured by determination of reference samples and participation in interlaboratory trials.
Concerning the follow-up, vital status of all participants was asked to all municipalities where they used to live and was unknown for only 25 subjects. The diagnosis of cancer was made by written contact with the general practitioners or/and oncologists of the deceased subjects as we received from the municipalities name and address of the certifying physician who in most of the cases was a hospital physician where death occurred. They had to answer a questionnaire on the certitude of the diagnosis. During 10-y follow-up respectively 790 male and 327 female subjects died and among them 252 male and 91 female subjects from cancer. No diagnosis was at hand for 8.1 and 8.9% of male and female deaths, respectively.
In 6.1 and 9.2% of male and female cancer deaths, respectively, no organ of origin could be found (in general metastasised cancers). The distribution of cancer deaths in function of time is the following: 4.0% during the first year of follow-up, 7.5% during the second year, and 88.6% between 2 and 10 y follow-up.
A nested case-control study was conducted within this cohort. We made a power calculation to determine the sample size required to detect a two-fold increase in odds for cancer death between lowest and highest tertile of selenium with 80% power at the 5% significance level. This could be achieved with 132 cases and 396 controls. We increased these numbers if we could afford, in order to ensure that the required sample size would be achieved in case of missing data.
A total of 201 cases were randomly selected from all cancer deaths. Their cancer site distribution was the same as in the total cohort. For each case, three controls matched for gender and age were selected at random from those at risk, at the time of case death. Ethical approval for the study was obtained by review committees of the University of Ghent and the Brussels Free University.
Statistical methods
The design being a nested case-control, with controls individually matched to cases, conditional logistic regression was used for both univariate and multivariate analyses to test Serum selenium and cancer mortalitythe association between baseline characteristics of study participants and cancer mortality. Conditional maximum likelihood method was used to estimate the parameters in the logistic models (Breslow et al, 1978; Breslow & Day, 1980) . Unadjusted and adjusted odds ratios (ORs) and their 95% confidence intervals (95% CI) were estimated from, respectively, univariate and multivariate logistic models. ORs are only presented for factors significantly associated with cancer mortality. Statistical significance was assessed according to the Wald w 2 statistic.
For the analyses, serum selenium as well as nutrients intake distributions were divided into tertiles according to the controls' distributions with subjects in the highest tertile chosen as the referent group.
Statistical analyses were performed using SPSS 10.0.5 for windows software (Nomura, 1990) .
Results Table 1A -C shows the baseline characteristics of both cases and controls. Cases present a higher prevalence of past or current smokers and almost no differences in fat, fibre and alcohol intake, whereas lower intakes for retinol, vitamin C and beta-carotene were observed in cases as compared to controls. Table 2 shows baseline average and median selenium for cases and controls. Mean selenium is lower in all cases compared to all controls because of a large difference in the male subjects.
Unadjusted relative risk of cancer deaths show a decrease across tertiles both for serum selenium and beta-carotene, the former with a 60% excess deaths for those with a selenium level lower than 72 mg/l (Table 3) . Table 4 shows a multivariate analysis separately for male and female subjects. As can be seen, serum selenium is an independent predictor of cancer mortality only in male subjects with a relative risk of first on third tertile of 2.2 with a P-value for trend of 0.018. In female subjects a nonsignificant direct relation is observed with those in the lowest tertile of selenium presenting the lowest cancer mortality.
Beta-carotene and cigarette smokers (ever/never) are other independent predictors of cancer mortality.
Finally, Table 5 gives average serum selenium in relation with cancer (at least three cases) at some sites in both male and female subjects. In male controls, the average selenium is 79.6 mg/l; all cancer deaths except those from prostate cancer as well as brain tumours show lower selenium values. In female controls, the mean serum selenium is 76.3 mg/l. Only the mean selenium of the seven cases with colon or rectal cancer and the three cases of pancreas cancer show Serum selenium and cancer mortality M Kornitzer et al *Multivariate conditional logistic regression; nonsignificant independent variables: BMI; total energy; total fat; saturated fat; alcohol intake; fibre; retinol and qvitamin C. Sensitivity study A total of 21 cases (16 male and five female subjects) of cancer death occurred during the first 2 y of follow-up. Excluding these cases does not change substantially the results in terms of univariate and multivariate relative risks and their CIs: T1/T3 is 2.2 (1.3-3.9) in male subjects and 0.6 (0.2-1.5) in female subjects (multivariate analyses).
Discussion
The present investigation is one of the very few studies addressing a nonselected sample of a whole country with a moderately high average serum selenium of 78.7 mg/l as compared to other European countries (Alfthan & Nève, 1996; Rayman, 2000) . This study confirms the inverse independent correlation of serum selenium with cancer mortality only in male subjects. Moreover, the average serum selenium levels for cases (at least three) are lower for almost all sites including lung, higher gastrointestinal tract colorectum, blood cancers and pancreas. Excluding deaths during the first 2 y does not affect the results. Concerning confounding factors, the study demonstrated that both selenium and tobacco smoking were independent predictors of cancer mortality. This confirms literature results indicating that smoking does not considerably influence serum selenium concentrations (Alfthan & Nève, 1996) . Similarly, fasting state is usually not considered as an important parameter influencing serum selenium (Alfthan & Nève, 1996) .
These results also confirm the generally observed absence of inverse correlation of selenium tissue levels with cancer incidence or mortality in female subjects.
Thus, three other prospective nested case-control studies did not observe a relation between serum selenium and cancer in female subjects. Willett et al (1983) in an American study with 46% of the 111 cases being female subjects did found almost the same mean serum selenium levels for cases and controls. Likewise in a Finnish study, 21 cancer cases and controls had identical mean selenium levels (Salonen et al, 1985) . Finally, Kok et al (1987) in a population sample from the town of Zoetermeer reported no differences in serum selenium levels for the 29 female cases as compared to matched controls. In the three studies, like ours, significant lower mean selenium levels were observed in male cases as compared to controls. No formal hypotheses concerning these gender differences are at hand or were formulated by the authors of these studies. We propose here two tentative hypotheses:
1. Only some specific cancers are sensitive to selenium deficiency, and these are more often found in male subjects as compared to female subjects. 2. There is a general higher threshold to low serum selenium sensitivity in female subjects.
Both the hypotheses could be tested, as suggested by Kok et al (1987) by pooling of data sets from different studies in order to have sufficient number of cancers for different sites in both male and female subjects.
As such, our study answers the criteria of prospective observational epidemiology: temporality, graded association and independence.
As already pointed out (see Introduction) observational epidemiological studies, both retrospective and prospective, show heterogeneous results. Methodological problems could be at issue: misclassification of selenium status because of a high intraindividual F as compared to a interindividual F variance (Garland et al, 1993) , a low variance of serum selenium in homogenous populations and lack of statistical power because of low incidence of specific cancers. Another possibility consists in differences in selenium intake at the 'ecological' level of whole populations. This was observed in a study investigating the association between US county forage selenium status and cancer mortality rates: consistent inverse associations were observed for several cancers with forage selenium status, although the possibility of confounding factors cannot be absolutely excluded (Clark et al, 1991) .
Several European countries or regions show low tissue selenium levels as compared to the US and Belgium (Alfthan & Nève, 1996; Nève, 2000; Rayman, 2000) . In Finland with a mean serum selenium of 54.3 mg/l before the nationwide selenium supplementation programme was introduced, high selenium intake is associated in some studies (Salonen et al, 1984; Knekt et al, 1990) , but not in all (Virtamo et al, 1987) , with a decrease in cancer mortality or incidence.
The same inverse association is observed in Sweden with a mean serum selenium of 88.3 mg/l (Fex et al, 1987) . On the other hand, in Norway with a high mean serum selenium (129 mg/l), selenium status is also inversely associated with cancer mortality (Ringstad et al, 1988) . The same is observed in the Netherlands (mean serum selenium 126 mg/l) (Kok et al, 1987) . In the US considered to be in the high range for selenium intake several studies did not observe a protective effect of high serum selenium levels (Willett et al, 1983; Schrober et al, 1987; Coates et al, 1988; Hunter et al, 1990; Garland et al, 1995) ; one of the more important features of those studies is that it addressed a high proportion of women.
In their monography published in 1997, the World Cancer Research Fund and the American Institute of Cancer Research stated that there is 'possible evidence' that diets high in selenium might protect against lung cancer, whereas the evidences for beneficial effects of selenium against stomach, liver and thyroid cancer were insufficient (World Cancer Research Fund in Association with American Institute for Cancer Research, 1997) .
In fact, causal association derived from high levels of evidence-based medicine was lacking at that moment. Since, at least three clinical trials were published two of them in China, a country with a very low selenium intake. How much do they contribute to demonstrating the causal relation between low selenium levels and higher risk of cancer incidence? Blot et al (1993) randomised 29 584 subjects aged 40-69 y from Linxian communes, a Chinese region known for a low intake of several micronutrients; only the arm supplemented with beta-carotene, vitamin E and 50 mg selenium showed a significant reduction of 9% in all-causes mortality (P ¼ 0.03) because of a 13% reduction in cancer rates especially stomach cancer (À21%). In this particular population, one was unable to measure the separate beneficial effects of selenium supplementation. An intervention trial in Qidong county, a region with a high incidence of hepatitis B surface antigen and consequently a high incidence of hepato cellular cancer (HCC), has shown that with a supplementation of 200 mg selenium yeast in hepatitis B carriers no HCC occurred during a 4-y follow-up against seven cases in the placebo group (Yu et al, 1997) .
In a US randomised controlled trial 1312 patients with a history of basal cell or squamous cell carcinomas of the skin aged 18-80 y were randomised to 200 mg of selenium per day or placebo. Whereas incidence of basal or squamous cell carcinomas of the skin, the primary outcome, was not reduced by selenium supplementation, several secondary outcomes showed a significant reduction in incidence: total cancer mortality (À50%), total cancer incidence (À37%), lung cancer incidence (À44%), prostate cancer incidence (À65%) and colorectal cancer incidence (À61%). This trial was stopped in advance of its planned termination because of the absence of an effect on the primary outcomes and a reduction in cancer mortality and cancer incidence. As the authors pointed out, the reported P-values should be interpreted with great care, since there is no generally accepted method for adjusting P-values when the early stopping is not based on the primary end point (Clark et al, 1996) .
The pathogenetic mechanisms by which low tissue selenium could induce and promote cancer have been discussed in several papers (Ip, 1986; Combs & Gray, 1998; Rayman, 2000) . Besides Finland, no European country, to our knowledge, have fertilisers used for grain crops been fortified with selenium with a consequent increase of selenium content of the Finnish food supply similar to those in North America (Varo et al, 1988) . Such a population prevention approach seems appropriate for a country such as Finland with a very low daily selenium intake. It is nevertheless of interest to note that despite an increase in the dietary selenium intake, from 45 mg/day in the early 1980s to 110-120 mg/day in 1987-1990, the cancer incidence in this country from 1983 to 1996 has not been significantly affected as compared with that of Sweden and/or Norway (Vinceti et al, 2000) . Moreover it will probably not answer the crucial question of the protective effect against specific cancers of selenium supplementation of about 200 mg/day.
Those cancer sites for which observational prospective studies as well as the Nutritional Prevention of Cancer Trial (Clark et al, 1996) have shown an inverse correlation with tissue selenium status, like lungs, upper gastrointestinal tract and prostate (Marshall, 2001) should become primary end points in placebo-controlled clinical randomised trials preferably to be performed in those countries with low range in human tissue selenium.
Our study shows some limitations. It cannot address the lack of data on the temporal relation of the date of blood sampling to the date of diagnosis of cancer as the endpoint is cancer mortality. However, exclusion of cases dying within the first two years after the baseline examination does not affect materially the results (see sensitivity study).
The high response rate of general practitioners and specialists concerning the cause of death makes selection and information bias unprobable but this cannot be completely ruled out.
This study was not designed in order to look at site-specific cancers in both genders but rather cancer deaths in a broad sense. Nevertheless the study confirms the fact, without statistical implication, that low serum selenium is related to a host of site-specific cancer deaths in male subjects only, confirming several observational and experimental studies.
Consequently, it may be hoped that the clinical trials related to specific cancer sites, now underway, will put the role of selenium in better perspective with regard to cancer prevention (Hercberg et al, 1998; Klein et al, 2001; Raich et al, 2001) .
